128 related articles for article (PubMed ID: 38834151)
21. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Delforge M; Shah N; Miguel JSF; Braverman J; Dhanda DS; Shi L; Guo S; Yu P; Liao W; Campbell TB; Munshi NC
Blood Adv; 2022 Feb; 6(4):1309-1318. PubMed ID: 34933328
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
Karampampa K; Zhang W; Venkatachalam M; Cotte FE; Dhanda D
J Med Econ; 2023; 26(1):243-253. PubMed ID: 36705644
[TBL] [Abstract][Full Text] [Related]
23. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
Shah N; Delforge M; San-Miguel J; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Miera M; Williams A; Murphy R; Devlen J; Hege K; Campbell TB; Munshi NC
Leuk Res; 2022 Sep; 120():106921. PubMed ID: 35930999
[TBL] [Abstract][Full Text] [Related]
24. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC; Oswald LB; Dillard CM; De Avila G; Nishihori T; Blue BJ; Freeman CL; Locke FL; Alsina M; Castaneda Puglianini O; Shune L; Sborov DW; Wagner C; Dima D; Hashmi H; Davis JA; Kocoglu MH; Badros AZ; Atrash S; Simmons G; Kalariya N; Ferreri C; Anderson LD; Afrough A; Kaur G; Lin Y; Liu L; Nadeem O; Voorhees P; Khouri J; McGuirk J; Sidana S; Hansen DK; Patel K
Blood Adv; 2024 Jan; 8(1):251-259. PubMed ID: 37855718
[TBL] [Abstract][Full Text] [Related]
25. Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma.
Cho HJ; Jo JC; Lee YJ; Lee MW; Kim DY; Shin HJ; Im SN; Lee JH; Bae SH; Do YR; Lee WS; Kim MK; Jung J; Lee JM; Kim JH; Baek DW; Sohn SK; Moon JH
Korean J Intern Med; 2023 Mar; 38(2):238-247. PubMed ID: 36698051
[TBL] [Abstract][Full Text] [Related]
26. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Logue JM; Peres LC; Hashmi H; Colin-Leitzinger CM; Shrewsbury AM; Hosoya H; Gonzalez RM; Copponex C; Kottra KH; Hovanky V; Sahaf B; Patil S; Lazaryan A; Jain MD; Baluch A; Klinkova OV; Bejanyan N; Faramand RG; Elmariah H; Khimani F; Davila ML; Mishra A; Blue BJ; Grajales-Cruz AF; Castaneda Puglianini OA; Liu HD; Nishihori T; Freeman CL; Brayer JB; Shain KH; Baz RC; Locke FL; Alsina M; Sidana S; Hansen DK
Blood Adv; 2022 Dec; 6(24):6109-6119. PubMed ID: 35939783
[TBL] [Abstract][Full Text] [Related]
27. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
Shah N; Mojebi A; Ayers D; Cope S; Dhanasiri S; Davies FE; Hari P; Patel P; Hege K; Dhanda D
J Comp Eff Res; 2022 Jul; 11(10):737-749. PubMed ID: 35485211
[No Abstract] [Full Text] [Related]
28. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.
Kirchberg J; Fischer L; Born P; Brunner F; Morgner C; Fürst D; Heyn S; Bach E; Brueckner M; Jentzsch M; Wang SY; Böttcher S; Franke GN; Schrezenmeier H; Platzbecker U; Merz M; Vučinić V
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38821728
[TBL] [Abstract][Full Text] [Related]
29. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
30. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J
N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253
[TBL] [Abstract][Full Text] [Related]
31. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
Oswald LB; Gudenkauf LM; Li X; De Avila G; Peres LC; Kirtane K; Gonzalez BD; Hoogland AI; Nguyen O; Rodriguez Y; Baz RC; Shain KH; Alsina M; Locke FL; Freeman C; Castaneda Puglianini O; Nishihori T; Liu H; Blue B; Grajales-Cruz A; Jim HSL; Hansen DK
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835405
[TBL] [Abstract][Full Text] [Related]
32. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M; Otero PR; Shah N; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Devlen J; Miera M; Gerould H; Campbell TB; Munshi NC
Leuk Res; 2023 Jun; 129():107074. PubMed ID: 37087950
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
[TBL] [Abstract][Full Text] [Related]
34. Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma.
Mejia Saldarriaga M; Pan D; Unkenholz C; Mouhieddine TH; Velez-Hernandez JE; Engles K; Fein JA; Monge J; Rosenbaum CA; Pearse R; Jayabalan DS; Gordillo CA; Chan HT; Yamshon S; Thibaud S; Mapara MY; Inghirami GG; Lentzsch S; Reshef R; Rossi A; Parekh S; Jagannath S; Richard S; Niesvizky R; Bustoros M
Blood Adv; 2024 May; ():. PubMed ID: 38776397
[TBL] [Abstract][Full Text] [Related]
35. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China.
Wu W; Ding S; Mingming Z; Yuping Z; Sun X; Zhao Z; Yang Y; Hu Y; Dong H
J Med Econ; 2023; 26(1):701-709. PubMed ID: 37145966
[TBL] [Abstract][Full Text] [Related]
37. Real-world analysis of teclistamab in 123 RRMM patients from Germany.
Riedhammer C; Bassermann F; Besemer B; Bewarder M; Brunner F; Carpinteiro A; Einsele H; Faltin J; Frenking J; Gezer D; Goldman-Mazur S; Hänel M; Hoegner M; Kortuem KM; Krönke J; Kull M; Leitner T; Mann C; Mecklenbrauck R; Merz M; Morgner A; Nogai A; Raab MS; Teipel R; Wäsch R; Rasche L
Leukemia; 2024 Feb; 38(2):365-371. PubMed ID: 38245601
[TBL] [Abstract][Full Text] [Related]
38. Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation.
John L; Sauer S; Hegenbart U; Dreger P; Hundemer M; Müller-Tidow C; Schmitt A; Schmitt M; Raab MS; Schönland SO
Transplant Cell Ther; 2023 Oct; 29(10):609.e1-609.e6. PubMed ID: 37348705
[TBL] [Abstract][Full Text] [Related]
39. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Lin Y; Raje NS; Berdeja JG; Siegel DS; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Massaro M; Petrocca F; Yeri A; Finney O; Caia A; Yang Z; Martin N; Campbell TB; Rytlewski J; Fuller J; Hege K; Munshi NC; Kochenderfer JN
Nat Med; 2023 Sep; 29(9):2286-2294. PubMed ID: 37592106
[TBL] [Abstract][Full Text] [Related]
40. Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
Clin Drug Investig; 2022 Dec; 42(12):1085-1092. PubMed ID: 36316586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
